Halozyme Therapeutic Expands Collaboration, License Deal With Argenx Over Development, Commercialization Of ENHANCE With Two Additional Targets
Benzinga Newsdesk 3 weeks ago
News
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize ENHANZE® with two additional exclusive targets.